Baseline circulating blood cell counts and ratios and changes therein for predicting immune-related adverse events during immune checkpoint inhibitor therapy: a multicenter, prospective, observational, pan-cancer cohort study with a gender perspective

Simple item page
dc.contributor.authorTeijeira, Lucía
dc.contributor.authorMartínez Kareaga, Mireia
dc.contributor.authorMoreno, Amaia
dc.contributor.authorElejoste, Ibone de
dc.contributor.authorIbáñez Beroiz, Berta
dc.contributor.authorArrazubi, Virginia
dc.contributor.authorDíaz de Corcuera, Isabela
dc.contributor.authorElejalde, Iñaki
dc.contributor.authorCampillo-Calatayud, Ana
dc.contributor.authorLes Bujanda, Íñigo
dc.contributor.departmentCiencias de la Saludes_ES
dc.contributor.departmentOsasun Zientziakeu
dc.date.accessioned2024-04-03T18:48:10Z
dc.date.available2024-04-03T18:48:10Z
dc.date.issued2024
dc.date.updated2024-04-03T18:12:31Z
dc.description.abstractSeveral factors have been associated with the occurrence of immune-related adverse events (irAEs) induced by immune checkpoint inhibitor (ICI) therapy. Despite their availability, the predictive value of circulating blood cell parameters remains underexplored. Our aim was to investigate whether baseline values of and early changes in absolute neutrophil count (ANC), absolute lymphocyte count (ALC), other blood cell counts, and lymphocyte-related ratios can predict irAEs and whether sex may differentially influence this potential predictive ability. Of the 145 patients included, 52 patients (35.8%) experienced at least one irAE, with a 1-year cumulative incidence of 41.6%. Using Fine and Gray competing risk models, we identified female sex (hazard ratio (HR) = 2.17, 95% confidence interval (CI) = 1.20–3.85), high ALC before ICI initiation (HR = 1.63, 95% CI = 1.09–2.45), and low ANC after ICI initiation (HR = 0.81, 95% CI = 0.69–0.96) as predictors of irAEs. However, ALC and ANC may only have an impact on the risk of irAEs in women (stratified for female sex, ALC-related HR = 2.61, 95% CI = 1.40–4.86 and ANC-related HR = 0.57, 95% CI = 0.41–0.81). Priority should be given to developing models to predict ICI-related toxicity and their validation in various settings, and such models should assess the impact of patient sex on the risk of toxicity.en
dc.description.sponsorshipThis research is supported by a grant for Health Research and Development Projects 2020 from the Basque Government (reference number: 2020111056).en
dc.format.mimetypeapplication/pdfen
dc.identifier.citationTeijeira, L., Martínez, M., Moreno, A., de Elejoste, I., Ibáñez-Beroiz, B., Arrazubi, V., Díaz de Corcuera, I., Elejalde, I., Campillo-Calatayud, A., Les, I. (2024) Baseline circulating blood cell counts and ratios and changes therein for predicting immune-related adverse events during immune checkpoint inhibitor therapy: A multicenter, prospective, observational, pan-cancer cohort study with a gender perspective. Cancers, 16(1), 1-13. https://doi.org/10.3390/cancers16010151.en
dc.identifier.doi10.3390/cancers16010151
dc.identifier.issn2072-6694
dc.identifier.urihttps://academica-e.unavarra.es/handle/2454/47828
dc.language.isoengen
dc.publisherMDPIen
dc.relation.ispartofCancers 2024, 16(1), 151, 1-13en
dc.relation.publisherversionhttps://doi.org/10.3390/cancers16010151
dc.rights© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.en
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectBlood cell countsen
dc.subjectBlood cell ratiosen
dc.subjectCanceren
dc.subjectGender perspectiveen
dc.subjectImmune checkpoint inhibitorsen
dc.subjectImmune-related adverse eventsen
dc.subjectPredictionen
dc.titleBaseline circulating blood cell counts and ratios and changes therein for predicting immune-related adverse events during immune checkpoint inhibitor therapy: a multicenter, prospective, observational, pan-cancer cohort study with a gender perspectiveen
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublication
relation.isAuthorOfPublication6cc547dc-8ec5-4b66-b920-358328d1f12c
relation.isAuthorOfPublication418894ee-b8db-443b-b46e-d993effb88da
relation.isAuthorOfPublication.latestForDiscovery6cc547dc-8ec5-4b66-b920-358328d1f12c

Files

Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
Teijeira_BaselineCirculating.pdf
Size:
905.01 KB
Format:
Adobe Portable Document Format
Download
Thumbnail Image
Name:
Teijeira_BaselineCirculating_MatCompl.pdf
Size:
3.48 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.78 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Artículos de revista DCS - OZS Aldizkari artikuluak
Artículos de revista - Aldizkari artikuluak